Inventor
JOHN MCWHIRTER
Inventor
US
Overview
Patents· 28 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A01Kprimary
A01KAnimal husbandry25%
C12NMicroorganisms or enzymes25%
C07KPeptides21%
A61FFilters implantable into blood vessels7%
A61KPreparations for medical, dental or toiletry purposes5%
G01NInvestigating or analysing materials by determining their chemical or physical properties5%
A61BDiagnosis4%
A61NElectrotherapy2%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations1%
PatentTitleYear
12,589,031Methods and systems for combined sonic and laser applications for the eye202612,582,105Genetically modified T cell receptor mice202612,564,514Patient interface device for laser methods and systems202612,543,711Non-human animals expressing pH-sensitive immunoglobulin sequences202612,538,905Mouse having a humanized b-cell activating factor gene202612,514,752Patient interface device for ophthalmic laser procedures202612,433,264Non-human animals having an engineered immunoglobulin lambda light chain locus202512,433,265Non-human animals having a humanized a proliferation-inducing ligand gene202512,409,068Patient interface devices and methods and systems for combined sonic and laser applications202512,389,888Mice expressing a limited immunoglobulin light chain repertoire202512,391,920Models of tauopathy202512,371,475Nucleic acids encoding anchor modified antibodies and uses thereof202512,356,967Immunoglobulin lambda light chain and uses thereof202512,295,354Non-human animals expressing exogenous terminal deoxynucleotidyltransferase202512,110,502Models of tauopathy202412,058,987Mouse having a humanized B-cell activating factor gene202411,932,859Nuclease-mediated DNA assembly202411,845,957Models of tauopathy202311,666,040Humanized non-human animals with restricted immunoglobulin heavy chain loci202311,583,446Patient interface device for ophthalmic laser procedures202311,576,984Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using202311,559,050Humanized non-human animals with restricted immunoglobulin heavy chain loci202311,528,895Genetically modified T cell receptor mice202211,357,217Humanized universal light chain mice202211,314,051System and method for laser generated corneal and crystalline lens incisions using a variable F/# optical system with aspheric contact interface to the cornea or rotating and adaptive optics202211,261,248Restricted immunoglobulin heavy chain mice202211,224,207Non-human animals expressing pH-sensitive immunoglobulin sequences202211,192,947Histidine engineered light chain antibodies and genetically modified non-human animals for generating same2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to REGENERON PHARMA (22)· patent assignee history
2021–2022Patents assigned to REGENERAN PHARMACEUTICALS INC (3)· patent assignee history
2021–2026Based in US· patent location history
2022–2026Patents assigned to LENSAR INC (6)· patent assignee history
2024–2026Based in IT· patent location history
2026Patents assigned to LENSAR LLC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 22 | 2021–2026 |
| LENSAR INC | 6 | 2022–2026 |
| REGENERAN PHARMACEUTICALS INC | 3 | 2021–2022 |
| LENSAR LLC | 1 | 2026 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 25 | 2021–2026 |
| IT | 3 | 2024–2026 |